CS
ENZY

Credit Suisse’s Enzymotec Ltd ENZY Stock Holding History

Credit Suisse’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16,096
Closed -$184K – 4342
2017
Q3 		$184K Buy
+16,096
New +$159K ﹤0.01% 3957

Other funds holding ENZY

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DG
Delek Group Herzliya, Israel $2.59B AUM 1.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GH
GAM Holding Zurich, Switzerland $1.57B AUM 25.73% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
CRA
Circle Road Advisors New York $27.7M AUM 35.85% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's ENZY Position: Q4 2017 in Review

Credit Suisse sold out of Enzymotec Ltd (ENZY) in Q4 2017, closing a stake of 16,096 shares — an estimated $184K sold.

Credit Suisse first reported a position in ENZY in Q3 2017 and held it in 1 quarter. The position peaked at $184K in Q3 2017. 37 funds tracked by Wall St. Rank hold ENZY as of Q4 2017.

  • Credit Suisse reported no remaining Enzymotec Ltd position as of Q4 2017 after selling out during the quarter.
  • Credit Suisse sold 16,096 Enzymotec Ltd shares in Q4 2017, an estimated $184K.
  • Credit Suisse first reported a position in Enzymotec Ltd in Q3 2017 and held it in 1 quarter.
  • Credit Suisse's Enzymotec Ltd position peaked at $184K in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q4 2017.

Based on Credit Suisse's 13F filing for Q4 2017, filed 14 Feb 2018.